DHR US S&P 500Russell 1000 Earnings call · transcribed from the recording
Danaher Corporation (DHR) · Q3 2026 results and valuation
Share price: $235.31 · 2026-11-11
Danaher Corporation provides equipment, consumables, and services for the biotechnology, life sciences, and diagnostics sectors. The company serves pharmaceutical companies, biotechnology firms, and research institutions across various global markets. Its operations include research, manufacturing, and distribution facilities located in numerous countries. Source: 10-K annual report (2026-02-24)
Results Q3 2026 vs Q2 2026 · previous quarter · published 21 Oct 2026 and 21 Jul 2026
Net income up 42.0% on the previous quarter. Management sounded very upbeat, though noticeably less so answering analysts.
1 · Numbers
+42.0%
Net income vs Q2 2026
Outlook given
Net income 1.24B vs 870.0M
Revenue +4.6%
Against the same quarter last year (Q3 2025) it is +36.0%, so it is not just seasonal.
Why Against the same quarter last year (+36.0%), net income rose because of improved in-market conditions and the benefit of strong commercial and operational execution across the portfolio, resulting in a nearly 30% adjusted operating profit margin.
2 · How management spoke
Very upbeat
More upbeat than 92% of company calls
Answers to analysts: upbeat, but clearly less so than the script.
Similar to last call.
3 · What stood out
Danaher Corporation increased its full year 2026 adjusted diluted net EPS guidance to a range of $8.57 to $8.62 from the previous range of $8.45 to $8.60.
Valuation
Is Danaher Corporation undervalued?
Reverse DCF. Free cash flow from the last full fiscal year (2025-12-31), grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.
At −2.7% growth a year (3-year revenue growth), the model's fair value is $39.76 a share — the stock trades 492% above it. Today's price assumes 15.5% growth a year.
Current price
$235.31
close of 2026-11-11
Market implies growth of iThe yearly free-cash-flow growth, for the next 10 years, that today’s share price already assumes. If you believe the company grows faster than this, the stock is cheap under this model; slower, and it is expensive.
+15.5% for 10 yrs
Fair value / share
$39.76
Buy below
$29.82
Price vs fair value
Overvalued >200%
Price vs buy-below price
Overvalued >200%
Read between the lines
-
Guidance
DHR increased its full year 2026 adjusted diluted net EPS guidance to $8.57 to $8.62 from the previous range of $8.45 to $8.60.
-
Guidance
DHR expects an adjusted operating profit margin of approximately 29.5% for the fourth quarter.
-
Figure
Core revenue growth excluding respiratory revenue improved to 5.5% and the company delivered a nearly 30% adjusted operating profit margin.
Source quote
“Core revenue growth, excluding respiratory revenue, improved to 5.5%, and we delivered a nearly 30% adjusted operating profit margin.”
-
Figure
Sales reached $6.6 billion with core growth of 5.5% excluding respiratory revenue, representing a 100 basis point acceleration from the second quarter.
Source quote
“Sales were $6.6 billion, and core growth, excluding respiratory revenue, was up 5.5%, and encouraging 100 basis points acceleration from the second quarter and a continuation of the improvement we've seen throughout the year.”
-
Figure
DHR generated $1.6 billion of free cash flow in the quarter and $4 billion for the first three quarters, resulting in a 128% free cash flow to net income conversion ratio.
Source quote
“We generated $1.6 billion of free cash flow in the quarter and $4 billion in the first three quarters of the year, resulting in a year-to-date free cash flow to net income conversion ratio of 128%, further underwriting the differentiated quality of our earnings.”
4 more
-
Key theme
Danaher aims to make it easier for customers to access the full strength of the company to solve their most important challenges.
Source quote
“We will make it easier for customers to access the full strength of Danaher and and look to us when trying to solve their most important challenges.”
-
Key theme
Biotechnology, life sciences, and diagnostics core revenue, excluding respiratory revenue, all grew mid-single digits or better in the third quarter, exceeding expectations on both the top and bottom line.
Source quote
“Our third quarter came in ahead of our expectations on both the top and bottom line, with biotechnology, life sciences, in diagnostics core revenue, excluding respiratory revenue, all growing mid-single digits or better.”
-
Key theme
M&A and capital deployment will continue to be essential drivers of Danaher's growth as they have been this quarter.
Source quote
“M &A and capital deployment have been essential drivers of Danaher's growth and will remain so.”
-
Figure
By continuously learning from each experiment, the platform is designed to help researchers move from idea to validated reagent up to eight times faster while generating up to 10 times higher volume compared to existing…
Source quote
“By continuously learning from each experiment, the platform is designed to help researchers move from idea to validated reagent up to eight times faster while generating up to 10 times higher volume compared to existing models, helping accelerate scientific discovery while providing the rigorous quality and reproducibility required to advance AI-driven drug discovery.”
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q3 2026. Ring: Q2 2026.
Management sounded noticeably less positive answering analysts than in its prepared script — a bigger drop than in 87% of calls. Scripts are polished in advance; a drop under questioning often marks the topics analysts pressed on, so the answers deserve a closer read than the script.
Sentences that drove the tone
“Danaher is already at the forefront of innovation, but I believe strengthening our innovation capabilities represents one of our largest opportunities to accelerate long-term growth.”
“The opportunity for Danaher is straightforward to become the defining leader in life sciences and diagnostics, a company that unambiguously gained share, delivers sustainable profitable growth, and helps our customers...”
“We believe that can accelerate profitable growth, drive share gains, and most importantly, help our customers improve outcomes for patients around the world.”
Full figures
USD · SEC EDGAR XBRL (10-Q, period end 2026-09-25)
| Metric | Q3 2026period end 2026-09-25 | Q2 2026period end 2026-06-26 | Change | Q3 2025 | YoY |
|---|---|---|---|---|---|
| Revenue | 6.55B | 6.26B | +4.6% | 6.05B | +8.3% |
| Gross profit | 3.84B | 3.61B | +6.3% | 3.52B | +8.9% |
| Operating income | 1.25B | 1.13B | +10.5% | 1.15B | +7.9% |
| Net income | 1.24B | 870.0M | +42.0% | 908.0M | +36.0% |
| EPS | 1.75 | 1.23 | +42.3% | 1.27 | +37.8% |
| P/E today 37.7 | 36.8 | 34.8 | +2.0 | 38.0 | −1.2 |
Topics
Most discussed now
- New The opportunity for Danaher is straightforward to become the defining leader in life sciences and diagnostics, a company that…
- New Danaher also has truly unique differentiators that continue to serve us well today.
- New When that Harvard case study was written, Danaher's businesses were lower growth markets and its customers typically bought from a...
- Danaher's adjusted operating profit margin of 29% was up 110 basis points and exceeded expectations, driven primarily by strong…
- China was up high single digits, with growth in all three of Danaher's segments.
Top topics in Q2 2026
- Nothing dropped away.
Latest announcements
Official filings, newest first. Summaries are generated from each filing and its attachment; every figure is checked against the source.
- Results of operations · SEC 8-K
Danaher reported third-quarter 2026 revenue of $6.6 billion, up 8.5% year-over-year, and net earnings of $1.2 billion, which increased 34.5% compared to the previous year.
- Director or officer change; Other events · SEC 8-K
Alan G. Spoon will retire from the Board at the 2027 annual meeting, and Steven M. Rales and Mitchell P. Rales waived their rights to 500,000 restricted stock units each.
- Director or officer change; Regulation FD disclosure; Other events · SEC 8-K
Danaher appointed Julie Sawyer Montgomery as President and CEO effective October 1, 2026, replacing Rainer Blair, who will retire after the Diagnostics platform grew from $6.0 billion in 2017 to $11.0 billion.
- Results of operations · SEC 8-K
Danaher reported second-quarter 2026 revenues of $6.3 billion, up 5.5% year-over-year, and net earnings of $870 million, which increased 60% compared to the previous year.
- New financial obligation; Other events · SEC 8-K
- Director or officer change; Shareholder vote results · SEC 8-K
Shareholders approved the Amended and Restated Danaher Corporation Omnibus Incentive Plan, which increases the share reserve by 20 million shares and extends the plan term to May 5, 2036.
- Material agreement; Other events · SEC 8-K
Danaher Corporation filed a Form 8-K on April 22, 2026, regarding material agreements and other events involving various senior notes due between 2026 and 2049.
- Results of operations · SEC 8-K
Danaher reported first-quarter 2026 revenues of $6.0 billion, up 3.5% year-over-year, with net earnings of $1.0 billion and non-GAAP adjusted diluted net earnings per common share increasing 9.5% to $2.06.
Catalyst calendar
management-stated targets — from the latest earnings call; plans, not promises.
-
fourth quarter
core revenue growth, excluding respiratory revenue, to be in the 4% to 5% range
Source quote
“In the fourth quarter, we expect core revenue growth, excluding respiratory revenue, to be in the 4% to 5% range.”
-
fourth quarter
adjusted operating profit margin of approximately 29.5%
Source quote
“Additionally, we expect a fourth quarter adjusted operating profit margin of approximately 29.5%.”
-
full year 2026
increasing our full year adjusted diluted net EPS guidance to $8.57 to $8.62
Source quote
“For the full year 2026, we are increasing our full year adjusted diluted net EPS guidance to $8.57 to $8.62 versus our prior range of $8.45 to $8.60.”
-
January
provide a more quantitative and detailed guidance outlook
Source quote
“We'll provide a more quantitative and detailed guidance outlook in January, but hopefully this gives you a helpful starting point for how we're thinking about next year.”
-
2026
bioprocessing core growth
Source quote
“So, no change to our full-year expectations for 2026 for bioprocessing, mid-single-digit core growth.”